MedTrace Logo

Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis

NCT01119339 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-05-29

No results posted yet for this study

Summary

The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)

Conditions

Interventions

DRUG

LAS 41004

LAS 41004 dosage 1, once daily

DRUG

LAS 41004

LAS 41004 dosage 2, once daily

DRUG

LAS 41004

LAS 41004 dosage 3, once daily

DRUG

LAS 41004

LAS 41004 dosage 4, once daily

DRUG

LAS 41004

LAS 41004 , dosage 5, once daily

DRUG

LAS 41004 dosage 6

LAS 41004, dosage 6, once daily

DRUG

Placebo

Placebo, once daily

DRUG

Reference

Reference, once daily

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Christoph Willers, MD, MBA · Almirall Hermal GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01119339 on ClinicalTrials.gov